NTHI — NEONC TECHNOLOGIES HOLDINGS, INC.

Nasdaq · Health Care · Pharmaceuticals · CIK 1979414 ·
Last close
$4.69
Market Cap
$121.64M
52W High
$5.82
52W Low
$3.01
ADV30
207,880
Next earnings
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -7,008,539 -8,819,932 3,330,161 138,601 16,561,326
Dec 2025 0 -13,625,675 -15,524,104 2,823,634 58,729 20,331,363
Sep 2025 0 -6,934,647 -8,615,920 4,082,916 1,513,224 15,897,186
Jun 2025 0 -5,708,034 -5,680,170 2,988,187 125,039 14,803,681

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-21,705,667
Investing CF
Financing CF
$16,905,056
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-2.91
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-121,574,587
Inventory
Receivables
ST Investments
EBIT TTM
$-35,461,857
Pretax Income TTM
$-38,640,126
Interest Exp TTM
$3,178,269
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$39,990
EBITDA
Free Cash Flow
$5,401,299
Enterprise Value
$118,067,296
Total Cash
$1,973,420
Total Debt
$328,217
Shares Out
25,936,365
Trailing EPS
$-2.12
Book Value
$-0.87
ROE
ROA
-635.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 39,990 -58,169,198 -62,146,210 2,823,634 20,331,363 -20,363,948
Dec 2024 83,000 -7,142,522 -11,898,464 3,417,241 8,922,202 -4,213,916
Dec 2023 70,462 -8,097,669 -14,921,065 1,265,376 15,253,629 -1,880,012
Dec 2022 20,000 -2,837,604 -3,046,757 728,682 2,304,093 -881,736

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.01

Peers — same industry

TickerNameMarket CapLastDaily %
GNLX GENELUX Corp $123.07M $2.72
ANIX Anixa Biosciences Inc $123.16M $3.62
ADCT ADC Therapeutics SA $123.21M $0.97
CPIX CUMBERLAND PHARMACEUTICALS INC $117.47M $7.84
COYA Coya Therapeutics, Inc. $116.35M $4.96

News headlines (Yahoo Finance, 1h cache)

NeOnc Technologies Holdings Inc (NTHI) (Q2 2026) Earnings Call Highlights: First Annual Meeting ...
2026-08-17 17:31 · Yahoo
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
2026-08-13 20:18 · Yahoo
NeOnc Technologies shares jump after positive Phase 2a glioma results
2026-08-12 13:39 · Yahoo
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
2026-08-10 13:42 · Yahoo
NeOnc Technologies Appoints Strategy and Finance Executive Nasim Shomali to its Board of Directors
2026-07-27 14:37 · Yahoo
NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition
2026-07-15 13:00 · Yahoo
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
2026-08-12 13:25 · Yahoo
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
2026-08-12 12:00 · Yahoo
NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
2026-08-11 12:44 · Yahoo

Recent Insider Activity

FiledTradeInsiderTitleType PriceQtyValue
2026-08-20 21:15:51 2026-08-18 Chen Thomas C CEO, 10% P - Purchase 5.49 12757 69998
2026-08-18 14:30:43 2026-08-18 Heshmatpour Amir F CEO, Pres, 10% P - Purchase 5.54 9000 49860